دورية أكاديمية
أعرض في EDS

Baseline levels determine magnitude of increment in 25 hydroxy vitamin D following vitamin D3 prescription in healthy subjects.

التفاصيل البيبلوغرافية
العنوان: Baseline levels determine magnitude of increment in 25 hydroxy vitamin D following vitamin D3 prescription in healthy subjects.
المؤلفون: Kaykhaei MA; Department of Internal Medicine, Ali-EbneAbitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.; Genetics of non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran., Khodadoost M; Department of Internal Medicine, Ali-EbneAbitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran., Dashipour AR; Department of Food Sciences and Nutrition, Zahedan University of Medical Sciences, Zahedan, Iran., Haidari Z; Department of Internal Medicine, Ali-EbneAbitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran., Karimkoshteh A; Department of Internal Medicine, Ali-EbneAbitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran., Sandoughi M; Department of Internal Medicine, Ali-EbneAbitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran. mahnazsandoughi@gmail.com.; Clinical Immunology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. mahnazsandoughi@gmail.com.
المصدر: Endocrine [Endocrine] 2019 May; Vol. 64 (2), pp. 378-383. Date of Electronic Publication: 2019 Mar 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE
أسماء مطبوعة: Publication: Feb. 1996- : Totowa, NJ : Humana Press
Original Publication: Houndsmills, Basingstoke, Hants, UK : Macmillan Press, c1994-
مواضيع طبية MeSH: Cholecalciferol/*therapeutic use , Vitamin D/*analogs & derivatives , Vitamin D Deficiency/*drug therapy, Adult ; Cholecalciferol/administration & dosage ; Dose-Response Relationship, Drug ; Female ; Healthy Volunteers ; Humans ; Male ; Treatment Outcome ; Vitamin D/blood ; Vitamin D Deficiency/blood ; Young Adult
مستخلص: Introduction: Vitamin D deficiency is a major health problem which affects about one billion people in the world. Although, vitamin D supplementation is recommended as standard treatment of vitamin D deficiency, there are controversies on dose response relationship. In this regard, the present study aimed to determine the impact of vitamin D3 supplement on raising of serum 25 hydroxyvitamin D[25(OH)D] in healthy subjects with varying degrees of vitamin D deficiency.
Materials and Methods: In this clinical trial 114 subjects with varying degrees of vitamin D deficiency were entered and divided into three groups: serum levels of 25(OH) D less than 10 ng/ml, 10-20 ng/ml, and 20-30 ng/ml. All of the participants were given 50,000 units vitamin D3 per week for 8 weeks, thereafter, changes in serum levels of vitamin D and PTH were evaluated at week twelve. The results were analyzed using SPSS version 16 and P < 0.05 was considered to be significant.
Results: Of the 114 vitamin D deficient subjects, serum level of vitamin D was below 10 ng/ml in 22 persons (19.3%), 10-20 ng/ml in 52 persons (45.6%) and 20-30 ng/ml in 40 persons (35.1%). Following vitamin D prescription all people with varying degrees of vitamin D deficiency obtained a favorable serum level. The increase in vitamin D levels were 26.4, 18.5, and 8.3 ng/ml, in individuals with baseline vitamin D levels below 10 ng/ml, 10-20 ng/ml and 20-30 ng/ml, respectively. The changes in 25(OH) vitamin D in all three groups were significant (P < 0.05), nonetheless no significant alterations in serum levels of PTH were observed (P > 0.05).
Conclusion: Our results indicated an inverse relationship between baseline serum levels of 25(OH) D and its increment following treatment with vitamin D3. Therefore, the magnitude of increments in serum 25(OH) D is greater in subjects with lower baseline levels of 25(OH) D.
References: J Gerontol A Biol Sci Med Sci. 2012 Nov;67(11):1205-11. (PMID: 22503994)
Osteoporos Int. 2018 Aug;29(8):1697-1711. (PMID: 29713796)
J Bone Miner Res. 1998 Aug;13(8):1238-42. (PMID: 9718191)
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. (PMID: 21646368)
Am J Epidemiol. 2017 Apr 15;185(8):720-726. (PMID: 28338905)
PLoS One. 2014 Nov 05;9(11):e111265. (PMID: 25372709)
Am J Clin Nutr. 1998 Oct;68(4):854-8. (PMID: 9771862)
Nutrients. 2018 May 03;10(5):. (PMID: 29751504)
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:22-7. (PMID: 24388948)
Endokrynol Pol. 2013;64(4):319-27. (PMID: 24002961)
Ann Intern Med. 2012 Mar 20;156(6):425-37. (PMID: 22431675)
Arab J Gastroenterol. 2013 Sep;14(3):113-5. (PMID: 24206739)
J Steroid Biochem Mol Biol. 2018 Jan;175:4-11. (PMID: 27693095)
Calcif Tissue Int. 1995 Jun;56(6):518-20. (PMID: 7648477)
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. (PMID: 21118827)
Endocrine. 2017 May;56(2):245-261. (PMID: 28390010)
BMJ. 2014 Apr 01;348:g2035. (PMID: 24690624)
Eur J Biochem. 1997 Nov 15;250(1):63-71. (PMID: 9431991)
PLoS One. 2016 Sep 22;11(9):e0163451. (PMID: 27657724)
Arch Intern Med. 2009 Oct 26;169(19):1806-8. (PMID: 19858440)
Am J Clin Nutr. 2007 Jun;85(6):1586-91. (PMID: 17556697)
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3368-3375. (PMID: 29931358)
J Clin Endocrinol Metab. 2013 Dec;98(12):4845-51. (PMID: 24037880)
BMJ. 2014 Apr 01;348:g1903. (PMID: 24690623)
Nat Rev Endocrinol. 2017 Aug;13(8):466-479. (PMID: 28387318)
Am J Clin Nutr. 2003 Jan;77(1):204-10. (PMID: 12499343)
PLoS One. 2010 Jun 14;5(6):e11088. (PMID: 20559424)
Am J Clin Nutr. 2001 Feb;73(2):288-94. (PMID: 11157326)
J Clin Endocrinol Metab. 2015 Apr;100(4):1469-76. (PMID: 25668290)
Neurol Genet. 2016 Sep 13;2(5):e97. (PMID: 27652346)
N Engl J Med. 2007 Jul 19;357(3):266-81. (PMID: 17634462)
Bone. 2018 May;110:321-325. (PMID: 29486367)
Autoimmun Rev. 2010 Sep;9(11):709-15. (PMID: 20601202)
Autoimmun Rev. 2013 Aug;12(10):976-89. (PMID: 23542507)
BMJ Open. 2012 Dec 13;2(6):. (PMID: 23242238)
Ann Nutr Metab. 2011;58(1):37-41. (PMID: 21304235)
J Clin Endocrinol Metab. 2012 Aug;97(8):2606-13. (PMID: 22701014)
Lancet. 2010 Jul 17;376(9736):180-8. (PMID: 20541252)
J Clin Endocrinol Metab. 1999 Nov;84(11):3988-90. (PMID: 10566638)
Sci Rep. 2017 Sep 4;7(1):10361. (PMID: 28871163)
Bioessays. 2004 Jan;26(1):21-8. (PMID: 14696037)
Lancet Diabetes Endocrinol. 2014 Jan;2(1):76-89. (PMID: 24622671)
Nutrients. 2013 Dec 16;5(12):5127-39. (PMID: 24352091)
فهرسة مساهمة: Keywords: Dose response relationship; Treatment; Vitamin D deficiency
المشرفين على المادة: 1406-16-2 (Vitamin D)
1C6V77QF41 (Cholecalciferol)
A288AR3C9H (25-hydroxyvitamin D)
تواريخ الأحداث: Date Created: 20190317 Date Completed: 20200511 Latest Revision: 20200511
رمز التحديث: 20231215
DOI: 10.1007/s12020-019-01881-5
PMID: 30877526
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-0100
DOI:10.1007/s12020-019-01881-5